Xeris Biopharma Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Xeris Biopharma Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-14.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 55% of Healthcare companies in United States.
Cash Locked Ratio
$40For every $100 of sales, $40 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $46 tied up three years earlier.
More money tied up than 80% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$52Sales grew 165% in 3 years; of every extra $100 of sales, $52 became extra profit.
Higher than 71% of Healthcare companies in United States.
Asset Productivity Ratio
+165% / +11%In 3 years sales changed by +165% while total assets changed by +11%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.6×Debt due within a year is covered 4.6 times by its yearly operating cash.
Higher than 80% of Healthcare companies in United States.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 77% of Healthcare companies in United States.
Tangible Assets Ratio
71%Of every $100 the company owns, $71 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 60% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 98% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Xeris Biopharma Holdings, Inc. made a loss over the last year. Xeris Biopharma Holdings, Inc. owes $1.02 for every $1 it owns. Xeris Biopharma Holdings, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossXeris Biopharma Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-203.41Xeris Biopharma Holdings, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$2.0 BThe total market value of all of Xeris Biopharma Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeXeris Biopharma Holdings, Inc.'s net worth is negative ($10 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.02×Xeris Biopharma Holdings, Inc. owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 88% of Healthcare companies in United States.
Dividend yield
NoneXeris Biopharma Holdings, Inc. does not currently pay a dividend.
Revenue growth
+44%Revenue rose 44% in the year to Dec 2025, and grew 38% a year on average over 3 years.
Profit growth
Back to profitXeris Biopharma Holdings, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
0.2%Xeris Biopharma Holdings, Inc. keeps $0 of every $100 of revenue as net profit.
Cash quality
51.7×Cash from Xeris Biopharma Holdings, Inc.'s business was 51.7× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
0.9×Xeris Biopharma Holdings, Inc.'s operating profit covered its interest costs 0.9 times in the year to Dec 2025.
Cash vs debt
Net debtXeris Biopharma Holdings, Inc. had $147 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Xeris Biopharma Holdings, Inc. owe compared with what it owns?
Xeris Biopharma Holdings, Inc. owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 88% of Healthcare companies in United States.
Does Xeris Biopharma Holdings, Inc. pay a dividend?
No. Xeris Biopharma Holdings, Inc. does not currently pay a dividend.
Is Xeris Biopharma Holdings, Inc.'s revenue growing?
Revenue rose 44% in the year to Dec 2025, and grew 38% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.